On Aug. 17, the Food and Drug Administration approved Zelboraf (vemurafenib) for patients with the BRAF V600E mutation who have late-stage or unresected melanoma. Zelboraf is the second drug for ...
The approval was based on data from the multicenter, double-blind, placebo-controlled phase 3 IMspire150 study. The Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab; Genentech) ...
The FDA has approved Zelboraf (vemurafenib tablets; Genentech and Plexxikon) for the treatment of metastatic or unresectable melanoma in patients whose tumors express the BRAF V600E gene mutation. A ...
The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most ...
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® ...
First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
The approval was based on an extension in progression-free survival in the phase 3 coBRIM study. The FDA has approved the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) as a ...
Last year, Array Biopharma pulled the NDA for its melanoma drug binimetinib when the FDA said its phase 3 data wouldn’t make the grade. Now, the Colorado-based biotech is logging a win as a ...
Zelboraf also has been approved by the European Commission, and in Switzerland, Israel, Brazil, New Zealand and Canada. Zelboraf is not recommended for use in melanoma patients who lack the BRAF V600 ...
The FDA has approved a new drug to treat skin cancer in its late stages. Zelboraf got the okay to treat late-stage melanoma, the most dangerous type of skin cance r, after it was shown to extend ...
A new Roche (OTC:RHHBY) cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp (NYSE: LH). The Roche drug Zelboraf was approved in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results